Adherence and patient'experiences with the use of erlotinib in NSCLC treatment: the influence on plasma concentration and the exploration of factors affecting the use in daily practice.

Trial Profile

Adherence and patient'experiences with the use of erlotinib in NSCLC treatment: the influence on plasma concentration and the exploration of factors affecting the use in daily practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2013

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms Caper
  • Most Recent Events

    • 24 May 2010 Planned end date changed from 1 Jul 2010 to 1 Dec 2010 Netherlands Trials Register record.
    • 18 May 2010 Status changed from planning to recruiting as reported by Netherlands Trials Register record.
    • 16 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top